Michael Baker
Psychiatric/Mental Health · Pascagoula, MSNPI 1891354114
Payments from drug & device makers
Across 201 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$955
- Lundbeck LLC$470
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$450
- Takeda Pharmaceuticals U.S.A., Inc.$311
- Teva Pharmaceuticals USA, Inc.$279
- Otsuka America Pharmaceutical, Inc.$197
- plus $931 from 14 others
What the payments were for
- Food & beverage$3,46696%
- Education$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $955 |
| Lundbeck LLC | 24 | $470 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $311 |
| Teva Pharmaceuticals USA, Inc. | 16 | $279 |
| Otsuka America Pharmaceutical, Inc. | 10 | $197 |
| Vanda Pharmaceuticals Inc. | 8 | $190 |
| Neurocrine Biosciences, Inc. | 6 | $137 |
| Sunovion Pharmaceuticals Inc. | 13 | $98 |
| Alkermes, Inc. | 5 | $92 |
| Axsome Therapeutics, Inc. | 4 | $77 |
| Eisai Inc. | 4 | $77 |
| Johnson & Johnson | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Almatica Pharma LLC | 2 | $34 |
| Tris Pharma Inc | 2 | $27 |
| Merck | 1 | $22 |
| Bausch Health US, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$3,593 in reported general payments places this provider in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $542 |
| Duloxetine Hcl | 15 | $310 |
| Mirtazapine | 23 | $253 |
| Aripiprazole | 13 | $185 |
| Risperidone | 17 | $184 |
| Trazodone Hcl | 22 | $115 |
| Sertraline Hcl | 21 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $34 | $10021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Pascagoula
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Rose CliffordGautier$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.